<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3205">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01919801</url>
  </required_header>
  <id_info>
    <org_study_id>HGT-FIR-096</org_study_id>
    <nct_id>NCT01919801</nct_id>
  </id_info>
  <brief_title>Blinded Safety &amp; Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Angioedema</brief_title>
  <official_title>Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety &amp; Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to compare the safety and efficacy of icatibant with placebo
      in the treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in
      Adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Angiotensin-converting enzyme inhibitors (ACE-Is) are the class of medications prescribed
      most frequently for the treatment of hypertension. They are also used post myocardial
      infarction as well as in patients with heart failure, diabetes mellitus, and chronic kidney
      disease. Approximately 35 to 40 million patients are on ACE-Is worldwide.

      Study HGT-FIR-096 is a multicenter, Phase III, randomized, double-blind, two-armed,
      placebo-controlled trial.  The study population will consist of 118 adult patients, 18 years
      of age or older, who present with an acute ACE-I-induced angioedema attack.  The primary aim
      of the study is to demonstrate that icatibant is significantly more effective than placebo
      in resolving attacks of angioedema caused by ACE-I based on the Time to Meeting Discharge
      Criteria (TMDC). Safety and tolerability, as well as the pharmacokinetics (PK), of icatibant
      will also be evaluated. Eligible patients will be randomized at a 1:1 ratio to receive a
      single sub-cutaneous injection of either 30 mg icatibant or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Meeting Discharge Criteria (TMDC).</measure>
    <time_frame>Day 0 - 1 Day</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time from study drug administration to the earliest time point at which patients meet prespecified discharge criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Icatibant.</measure>
    <time_frame>Day 0 - Day 3 (+2 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of adverse events, injection site reactions, clinical laboratory testing, vital sign measurements, electrocardiogram (ECG) recordings, and physical examination findings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Symptom Relief (TOSR).</measure>
    <time_frame>Day 0 - Day 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of airway intervention due to ACE-I-induced angioedema.</measure>
    <time_frame>Day 0 - Day 3 (+2 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to the hospital or intensive care unit (ICU).</measure>
    <time_frame>Day 0 - Day 3 (+2 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioedema attack following study drug administration.</measure>
    <time_frame>Day 0 - Day 3 (+2 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to meeting discharge criteria (TMDC).</measure>
    <time_frame>4, 6, and 8 hours post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Characterization of the pharmacokinetic (PK) profile of icatibant</measure>
    <time_frame>45 minute and 2 hours (Â±10 minute) post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentration [Cmax] and area under the curve [AUC]</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Angiotensin Converting Enzyme Inhibitor Induced Angioedema</condition>
  <arm_group>
    <arm_group_label>Icatibant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo  will be administered as a single subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icatibant</intervention_name>
    <description>Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema</description>
    <arm_group_label>Icatibant</arm_group_label>
    <other_name>Firazyr</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 years of age or older.

          2. Patient is currently being treated with an ACE inhibitor.

          3. Patient presenting with an ACE inhibitor-induced angioedema attack of the head and/or
             neck region within 12 hours of onset (must be sufficiently less than 12 hours to
             allow study drug to be given with 12 hours of onset).

          4. Angioedema must be considered at least moderate in severity.

          5. Patient must have voluntarily signed an Institutional Review Board/Independent Ethics
             Committee-approved informed consent form after all relevant aspects of the study have
             been explained and discussed with the patient.

          6. Females must have a negative urine pregnancy test prior to administration of the
             study medication, with the exception of those females who have had a total
             hysterectomy or bilateral oophorectomy, or who are 2 years post-menopausal.

        Exclusion Criteria:

          1. Patient has a diagnosis of angioedema of other etiology (eg, hereditary or acquired
             angioedema, allergic angioedema [eg, food, insect bite or sting, evident clinical
             response to antihistamines and/or corticosteroids], anaphylaxis, trauma, abscess or
             infection or associated disease, local inflammation, local tumor, post-operative or
             post-radiogenic edema, salivary gland disorders, other [non-ACE inhibitor] drug
             induced angioedema).

          2. Patients with a family history of recurrent angioedema.

          3. Patients who have had a previous episode(s) of angioedema while not on ACE inhibitor
             therapy.

          4. Patients with acute urticaria (itchy, erythematous wheals).

          5. Patients who have an intervention to support the airway (eg, intubation, tracheotomy,
             cricothyrotomy) due to the current attack of angioedema.

          6. Patient has any of the following vascular conditions that, in the judgment of the
             investigator, would be a contraindication to participation in the study.

               -  Unstable angina pectoris or acute myocardial ischemia.

               -  Hypertensive urgency or emergency (diastolic blood pressure [DBP] &gt;120mm Hg or
                  systolic blood pressure [SBP] &gt;180 mm Hg).

               -  Within 1 month of a stroke or transient ischemic attack.

               -  New York Heart Association (NYHA) heart failure Class IV.

          7. Patient has a serious or acute condition or illness that, in the judgment of the
             investigator, would interfere with evaluating the safety and/or efficacy assessments
             of the study.

          8. Patient is pregnant or breast feeding.

          9. Patient has participated in another investigational study in the past 30 days.

         10. Patient is unable to understand the nature, scope, and possible consequences of the
             protocol, or is unlikely or unable to comply with the protocol assessments, or is
             unlikely to complete the study for any reason.

         11. Patients who are not suitable for the study in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Kimura, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire Human Genetic Therapies, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MedInfo Shire HGT</last_name>
    <phone>+1-866-888-0660</phone>
    <email>US_ShireHGT_Medicalinformation@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Blair</last_name>
      <phone>858-822-6599</phone>
      <email>jcblair@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Reidl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Department of Allergy</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Caine</last_name>
      <phone>510-752-1799</phone>
      <email>lisa.caine@kp.org</email>
    </contact>
    <investigator>
      <last_name>Peg Strub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ermira Brasha-Mitchell</last_name>
      <phone>202-715-5257</phone>
      <email>ermira.brasha@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michael Seneff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Dinneen</last_name>
      <phone>202-877-4593</phone>
      <email>jessica.dinneen@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Diane Sauter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shands Hospital at The University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Jones, MPH</last_name>
      <phone>352-265-5911</phone>
      <email>jnjones@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Marie-Carmelle Elie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Willett, RN</last_name>
      <phone>321-841-9623</phone>
      <email>paula.willett@orlandohealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Kristine Sernulka, RN</last_name>
      <phone>(321) 841-3685</phone>
      <email>kristine.sernulka@orlandohealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kurt Weber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Sanchez</last_name>
      <phone>813-844-3162</phone>
      <email>slsanchez@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Jason Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook County Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Xamplas, Pharm. D</last_name>
      <phone>312-864-3070</phone>
      <email>rxamplas@cookcountyhhs.org</email>
    </contact>
    <investigator>
      <last_name>Jacob Samuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal Health Care Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60064-3048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Nyland</last_name>
      <phone>224-610-2017</phone>
      <email>jill.nyland@va.gov</email>
    </contact>
    <investigator>
      <last_name>Rohit Arora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Scott</last_name>
      <phone>309-669-1109</phone>
      <email>ashley.scott@osfhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>William Tillis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Stewart, RN</last_name>
      <phone>504-842-0377</phone>
      <email>sarstewart@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Eiman Jahangir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Science Center</name>
      <address>
        <city>New OrlÃ©ans</city>
        <state>Louisiana</state>
        <zip>70070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grant Johnson, MPH</last_name>
      <phone>504-903-3594</phone>
      <email>gjohnso@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Moreno-Walton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gentry Wilkerson</last_name>
    </contact>
    <contact_backup>
      <phone>(410) 328-8025</phone>
      <email>gentrywlk@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gentry Wilkerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Keogh</last_name>
      <phone>617-724-1714</phone>
      <email>akeogh@partners.org</email>
    </contact>
    <investigator>
      <last_name>Aleena Banerji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gintas Krisciunas</last_name>
      <phone>617-414-1756</phone>
      <email>gintas.krisciunas@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Aianand Devaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddharth Parmar</last_name>
      <phone>617-525-8466</phone>
      <email>sparmar@partners.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Pallin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fidela Blank, MBA, RN</last_name>
      <phone>413-794-8680</phone>
      <email>fidela.blank@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Howard Smithline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Nico</last_name>
      <phone>248-605-1069</phone>
      <email>nkriste1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Howard Klausner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Medado, CCRP, MSc</last_name>
      <phone>313-745-4621</phone>
      <email>pbmedado@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Phillip Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oaks</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Grace</last_name>
      <phone>248-898-7382</phone>
      <email>hgrace@beaumont.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Swor, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Michigan</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarisa Hodge, &quot;BA, CCRC&quot;</last_name>
      <phone>314-996-8339</phone>
      <email>thodge@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>James Wedner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Marsack</last_name>
      <phone>248-964-8168</phone>
      <email>pamela.marsack@beaumont.edu</email>
    </contact>
    <investigator>
      <last_name>Aveh Bastani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cassandra Hosfield</last_name>
      <phone>612-873-9528</phone>
    </contact>
    <investigator>
      <last_name>James Miner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Dalton, BA</last_name>
      <phone>314-362-8024</phone>
      <email>daltonc@wusm.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nevada Access To Research and Education Society</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacki Griffin, RN</last_name>
      <phone>702-384-9101</phone>
      <email>nares2lvjackie@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Joanne Petruso, MSN, RN</last_name>
      <phone>(702) 384-9101</phone>
      <email>nares2lv@aol.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jim Christensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspira Health Network</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samaresh Dasgupta, DO</last_name>
      <phone>856-641-8000</phone>
      <email>dasgupta.sjh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Samaresh Dasgupta, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorraine Griner, CCRP</last_name>
      <phone>505-272-6257</phone>
      <email>lgriner@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Cameron Crandall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Jacob</last_name>
      <phone>718-245-2976</phone>
      <email>sjacob.cardiostudies@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Richard Sinert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings County Hospital Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marijayne Bushey</last_name>
      <phone>718-245-2973</phone>
      <email>mjbstrokestudies@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Jacob</last_name>
      <phone>(718) 245-2976</phone>
      <email>sjacob.cardiostudies@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Sinert, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuhair Ali</last_name>
      <phone>718-661-7306</phone>
      <email>zua9005@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Michael Radeos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allison Mainhart</last_name>
      <phone>252-744-5568</phone>
      <email>farmera@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>John Gough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathlyn Franklin</last_name>
      <phone>513-235-7971</phone>
    </contact>
    <investigator>
      <last_name>Jonathan Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracy Barbour</last_name>
      <phone>216-444-0231</phone>
      <email>barbout@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Sharon Mace, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Gahanna</city>
        <state>Ohio</state>
        <zip>43230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hill</last_name>
      <phone>614-293-6185</phone>
      <email>Michael.Hill@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Dick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Health</name>
      <address>
        <city>Chambersburg</city>
        <state>Pennsylvania</state>
        <zip>17201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Green</last_name>
      <phone>717-267-4880</phone>
      <email>cgreen@summithealth.org</email>
    </contact>
    <investigator>
      <last_name>Aylmer Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romy Nocera, PhD</last_name>
      <phone>215-762-3839</phone>
      <email>rnocera@drexelmed.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sona Byregowda</last_name>
      <phone>215-456-6673</phone>
      <email>byregows@einstein.edu</email>
    </contact>
    <investigator>
      <last_name>J. Kowalski, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SueAnn Livingston</last_name>
      <phone>412-359-8763</phone>
      <email>saliving@wpahs.org</email>
    </contact>
    <investigator>
      <last_name>Arvind Venkat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Bertsch, CCRP</last_name>
      <phone>401-444-9264</phone>
      <email>kbertsch@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Gregory Jay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Clinical Trials</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgia Welnick</last_name>
      <phone>803-434-4795</phone>
      <email>georgia.welnick@palmettohealth.org</email>
    </contact>
    <investigator>
      <last_name>William Owens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Max Castillo</last_name>
      <phone>214-820-9907</phone>
      <email>maxa.castillo@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>John Garrett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Peter Smith Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rani Jayswal</last_name>
      <phone>817-702-5891</phone>
      <email>rjayswal@jpshealth.org</email>
    </contact>
    <investigator>
      <last_name>Hao Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maudie Byrd</last_name>
      <phone>409-772-2440</phone>
      <email>mbyrd@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>Rana Bonds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Keene</last_name>
      <phone>713-873-7042</phone>
      <email>kelly.keene@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Spencer Greene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lea Baker</last_name>
      <phone>434-243-7375</phone>
      <email>lhb2k@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>David Burt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrine DeMone</last_name>
      <phone>(902) 494-6189</phone>
      <email>Corinne.DeMone@cdha.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Sam Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Reid, RN</last_name>
      <phone>(613) 548-1339</phone>
      <email>reidj@kgh.kari.net</email>
    </contact>
    <investigator>
      <last_name>Marco Sivilotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>July 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACE-I</keyword>
  <keyword>Firazyr</keyword>
  <keyword>icatibant</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Icatibant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
